Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive ...

Eli Lilly has signed its second pipeline-building deal in two days, reaching an agreement to buy in vivo CAR-T developer Orna ...

The new year brought a slew of new faces in the pharma and biotech world, especially in the top jobs, with a number of CEO ...

The 466,000 sq ft centre will serve as a hub to join Novartis' current R&D sites in Cambridge, Massachusetts, and Basel, ...

Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D collaboration that includes a $350 million upfront payment.

Many companies have tried to jump into the GLP-1 gold rush with their own versions of the blockbuster obesity drug. Prive Bio, whose CEO Laurent Audaly met with pharmaphorum’s Jonah Comstock last ...

Wegovy is the first GLP-1 to be available in the US for weight loss in an oral formulation, and Novo Nordisk has already reported strong take-up, with 170,000 people taking the drug as of last week, ...

"The government has claimed that the deal will only cost around £1 billion per year, but the UK's new commitment to double ...

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but ...

A wireless sensor the size of a paperclip, Abbott's CardioMEMS HF, can be used routinely by the NHS to monitor patients with ...

Incubated by Flagship Pioneering, Generate applies AI to teasing out the three-dimensional structure of human proteins, ...

Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits, fuelled ...